#1 Clinical Trials Search in Europe

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

3 1 1 1

What is this study about?

The study involves adults who have type 2 diabetes mellitus, a condition where the body does not use insulin properly, leading to high blood sugar. Participants will receive either the experimental tablet elecoglipron or the already approved oral medication semaglutide, both taken by mouth. The goal is to see how well each medicine controls blood sugar and affects body weight.

The purpose of the study is to compare the effectiveness of the two drugs for lowering blood sugar levels, measured by HbA1c, a lab test that shows average blood sugar over the past few months. Adults will be assigned to one of the two treatment groups and will take the assigned tablet each day for about one year. During this time, they will have regular clinic visits for simple checks such as blood draws and weight measurements, allowing researchers to track changes in blood sugar control and weight without any invasive procedures.

1 randomization

after joining the study you will be randomly assigned to receive either the test medication elecoglipron or the comparator medication semaglutide (brand name rybelsus). the assignment is made by the study team and you will not choose the group.

2 baseline assessments

before starting any medication you will have a series of baseline measurements. these include a blood test to determine your hbA1c level (a measure of average blood sugar), a measurement of your body weight, and a review of your medical history related to type 2 diabetes mellitus.

3 start of study medication

once randomization is complete you will begin taking the assigned tablet each day. the comparator tablets contain semaglutide and are available in strengths of 1.5 mg, 4 mg, and 9 mg; the exact dose you receive will follow the study dosing schedule. the test tablets contain elecoglipron; the specific dose is listed as 00 mg in the study documentation and will be administered as directed by the study protocol. all tablets are taken by mouth.

4 regular monitoring visits

throughout the 52‑week treatment period you will attend scheduled visits to check your safety and how well the medication is working. during each visit the study staff will repeat the hbA1c test, measure your body weight, and ask about any side effects or other health changes.

5 mid‑study assessments

at the middle of the study (around week 26) additional assessments may be performed to further evaluate blood sugar control and weight changes. these assessments follow the same procedures as the baseline and regular visits.

6 final assessment at week 52

at the end of week 52 you will undergo the final set of measurements. this includes a blood test for hbA1c, a measurement of body weight, and a summary of any adverse events experienced during the study. the results will be used to determine the effectiveness of the study medication compared with semaglutide.

7 study completion

after the week‑52 visit you will stop taking the study medication. the study team will provide instructions for any follow‑up care and will inform you about the overall study findings when they become available.

Who Can Join the Study?

  • Be diagnosed with type 2 diabetes mellitus (a condition that raises blood sugar) for at least 90 days before the screening visit.
  • Have diabetes that is not well controlled by diet, exercise, or up to two oral medicines that lower blood sugar.
  • Have a blood test called HbA1c that shows a level of 7% or higher but not more than 10.5% (this test measures average blood sugar over the past 2‑3 months).
  • Have a higher chance of heart problems, defined as having at least one of the following: proven coronary heart disease (narrowed heart arteries), peripheral arterial disease (narrowed arteries in the legs), ischemic cerebrovascular disease (reduced blood flow to the brain), or heart failure classified as NYHA class II‑III (moderate symptoms). Alternatively, having two or more risk factors for heart disease also qualifies.
  • Have a body mass index (BMI)</b) of 23 kg/m² or higher at the screening visit (BMI is a measure of body weight relative to height).
  • Have a stable body weight (no major weight loss or gain) for at least 90 days before screening, as reported by yourself or shown in medical records.

Who Cannot Join the Study?

  • Having type 1 diabetes mellitus, secondary forms of diabetes (including those present from birth), or a past episode of diabetic ketoacidosis (a dangerous condition where blood sugar is very high and creates acid) or hyperosmolar coma (extremely high blood sugar leading to loss of consciousness).
  • Currently receiving or planning to receive treatment for diabetic retinopathy (damage to the eye’s blood vessels caused by diabetes) or macular edema (swelling in the central part of the retina).
  • Having had more than one episode of severe hypoglycemia (dangerously low blood sugar) in the 180 days before screening, or a history of hypoglycemia unawareness (not feeling the warning signs of low blood sugar) or poor recognition of low‑sugar symptoms.
  • Having a clinically important condition that affects the upper gastrointestinal (GI) tract (the stomach and upper intestine), or regularly using any medication that changes gastric motility (how the stomach moves food) or gastric emptying (how quickly the stomach empties its contents).
  • Having a history of acute (sudden) or chronic (long‑term) pancreatitis (inflammation of the pancreas).
  • Having severe congestive heart failure classified as NYHA class IV (the most advanced stage where symptoms occur even at rest).
  • Having a personal or family history of medullary thyroid cancer (a specific type of thyroid cancer) or multiple endocrine neoplasia type 2 (an inherited condition that causes tumors in several hormone‑producing glands).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Diabetes-Zentrum-Wilhelmsburg GbR Hamburg Germany
Gyncentrum Sp. z o.o. Katowice Poland
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Acibadem City Clinic Diagnostic And Consultation Center Tokuda EAD Sofia Bulgaria
Diabeteszentrum Hamburg West Hamburg Germany

Other Sites

Site Name City Country Status
Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o. Poznan Poland
Ospedale San Raffaele S.r.l. Milan Italy
Azienda Ospedaliero Universitaria Di Modena Modena Italy
Azienda Universitaria Ospedaliera Consorziale Policlinico Bari Bari Italy
Dxnqtcocgutyerf Dnhjcwqf Mlpcs Duisburg Germany
Idvzzagl fezn Dkmxaaptizfktoxyz Mnllsbhw Gvsf Munster Germany
Ualkvssbuezjmyfjgqwvd Ekelpkxm Ahy Erlangen Germany
Kutrrelf Cxydkzyn gqpjp Chemnitz Germany
Zosoaai fvyg kvetrhjvp Sdjalng Sfebcrgpqwdskab Gqtv Elsterwerda Germany
Hpqh Uvx Dvbgospbqvfsohg Ntk Bzp Ovcmcuefha Ueavypxtosoqdkmooim Duo Rwmncgldkbkdbrgxb Bblwfd Bad Oeynhausen Germany
Retrcs Ilgmhlbz fojt mwmvlinqdwib Scpcxwo ucc Fafrgezmcfd Gneg Oldenburg In Holstein Germany
Mixqeycvevuir Vlejlvjpizxpcfozpp Ac Bsraedh Suiuuso Gom Berlin Germany
Hkurcvqmgcemjun Bwcrhsjvw Gladbeck Germany
Zokktqf fgh Kdrogcxyz Slyhwey Gzly St. Ingbert Germany
Pppykloqbmtspvueqa Ddjvg Damme Germany
Zepfsmu fcs Kyphkjrac Frboqxpph Alngds Oxvqewnfiipc Wangen Germany
dsopznjsvkiaiweixjbiu Zxi Dya Jgme Lztomzpk Falkensee Germany
Ucebjxwwwl Og Dijwzadg Debrecen Hungary
Otwatf Etmpfjetqarsa Cpwxjqw Kbhk Dunaújváros Hungary
Czixsapu Kllb Budapest Hungary
Zwao Mezsfi Sacce Rzgcvu Kleemr Zalaegerszeg Hungary
Uknwhcbmmo Og Syhydr Szeged Hungary
Jjppfaisfqtmudmzuxze Vamecxdah Hyweead Gadc Kbeqizybhviwlpsbmmkkc Szolnok Hungary
Nfhlzo Vqgnqiaec Swupu Lwzmd Kdsoke Salgotarjan Hungary
Mchtnohs Kxsh Budapest Hungary
Cokgopq Mtzloxqm Dhlojhnud Radom Poland
Evakon Shj z oebq Lublin Poland
Pkkmoneff Immogrnv Mdwdfuhn Mrvohrytpcvc Soqmn Wwlealctmojj I Axmbxyzmviswx Warsaw Poland
Ccnmcnfdc Duicneu Neqen Ssy ka Bialystok Poland
Msxvpjub Cqbexgr Dixtmpacivgauvugvubsoiutgvotvvpaqnldtxlegzyrfm Ddycxisvqcbmp Swv z ohbm Cracow Poland
Cnvtvzd Todwlwz Wvjrvxohuecu Jvuw Jqjxdwmtzinp Sgsjje Lodz Poland
Mqpjqmp Cuetoc Bigbyjjs Lzho Yambol Bulgaria
Aucpaal Oooagwxlbus Utuboafhjutdm Flayeeog Is Dn Nwrloa Naples Italy
Apooehy Ufiwy Shoaaoyvj Ltqeic De Biptcdl Bologna Italy
Cooggh Cvbhlnhrfwsp Mrjpwwj Sbazbs Milan Italy
Utonthmnzu Dlnqa Szjgm De Rtqr Lc Sptjmadb Rome Italy
Ueowczkgsz Mwbktyyzytpn Hrljljur Ffw Accuaz Tegtkthoe Kmjjdxw Eyzg Plovdiv Bulgaria
Cmqw &azbfho Cbvjtc fjh Atcqcdoe Sbpqfax aan Txrhlczjfb dn Celbog Chieti Italy
Mfattaf Aeer Mpedmur Doqvks Cgcqvc Eczo Sofia Bulgaria
Gtlculcsumiilclcjhe Dpb Tzkyfhqld / Dpk Bzqubrg Leipzig Germany
Dgxbcxzyshasnjk Sepaamcebdwhyumqw Pcpwt Pirna Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Bulgaria Bulgaria
Recruiting
06.07.2026
Germany Germany
Recruiting
06.07.2026
Hungary Hungary
Recruiting
06.07.2026
Italy Italy
Recruiting
06.07.2026
Poland Poland
Recruiting
06.07.2026

Trial locations

Investigated Drugs:

Semaglutide (Rybelsus) is a medication taken by mouth that is already approved for treating type 2 diabetes. In this study it is used as the standard treatment, or “comparator,” so researchers can see how well the new drug works compared to a medicine that doctors already know is effective. Participants will take semaglutide tablets during the trial, and the researchers will measure how it controls blood sugar and any side effects.

Elecoglipron is the experimental drug being tested in this trial. It is also taken by mouth as a film‑coated tablet. The study is looking at whether elecoglipron can lower blood sugar, be safe to use, and be tolerated well by people with type 2 diabetes. Participants receiving elecoglipron will be compared to those taking the standard semaglutide tablets to see if the new drug works better, the same, or worse.

type 2 diabetes mellitus – Type 2 diabetes mellitus is a chronic condition where the body does not use insulin properly, leading to high blood sugar. Over time, the pancreas may produce less insulin, causing glucose levels to rise further. The condition often develops slowly and may start with mild symptoms such as increased thirst and frequent urination. As it progresses, blood sugar may remain elevated between meals and after fasting. The ongoing excess sugar can affect many organs and may lead to changes in vision, nerve function, and circulation.

Trial ID:
2025-523933-24-00
Protocol code:
D7261C00005
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Hungary Poland Romania Slovakia Spain

  • A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia Germany Poland